TTUHSC Graduate School of Biomedical Sciences
HomeBiomedical SciencesFaculty and Staff

GSBS Faculty Details

Profile for Xinli Liu, PhD

Xinli Liu

Xinli Liu, PhD

  • Adjunct Assoc Professor Pharmaceutical Sci Amarillo
Office Phone: 806-414-9241
Mail Address: 1406 S Coulter St
Amarillo TX 79106-1786


Dr. Liu joins the Pharmaceutical Sciences faculty in the Fall of 2008 as an Assistant Professor. She received a B.S. in Chemistry from Lanzhou University (China; 1999) and earned her Ph.D. at the University of Kentucky (2004). She completed a postdoc fellowship in Institute of Pediatric Clinical Research, Division of Hematology and Oncology at Children’s Hospital Los Angeles, University of Southern California (2007).

Research Interests

Chemotherapy is an important approach in the treatment of human cancer. Many conventional anticancer drugs do not discriminate between cancerous and normal cell types and were consequently accompanied by dose limiting toxic side effect. Our main research interest is to develop molecularly targeted nanocarrier systems such as nanoparticles and conjugates to improve tumor drug delivery while avoiding healthy cells.

Selected Publications:

  • Wang, Xiaolei & Wu, Erxi & Wu, Jun & Wang, Tian-Li & Hsieh, Hsing-Pang & Liu, Xinli An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. PLoS One, 2013 Jun 6;8(6):e65686..
  • Qhattal, Hussaini & Liu, Xinli Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm., 2011 Aug 1;8(4):1233-46.
  • Mittapalli, Rajendar & Liu, Xinli & Adkins, Chris & Nounou, Mohamed & Bohn, Kaci & Terrell, Tori & Qhattal, Hussaini & Geldenhuys, Wener & Palmieri, Diane & Steeg, Patricia & Smith, Quentin & Lockman, Paul Paclitaxel-Hyaluronic Nano-Conjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model. Mol Cancer Ther., 2013 Sep 3. [Epub ahead of print].
  • Liu, Li & Beck, Haley & Wang, Xiaolei & Hsieh, Hsing-Pang Hsieh & Mason, Ralph & Liu, Xinli Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts. PLoS One, 2012;7(8):e43314.